Cambridge, UK, 06 October 2015: Abcam plc, a global leader in the supply of life sciences research tools, today announced the launch of its anti-PD-L1 primary antibody (clone 28-8). Produced using Abcam’s RabMAb® recombinant monoclonal antibody technology, the clone offers highly specific and reproducible antigen recognition to a checkpoint inhibitor critical to current cancer immunology research.
Programmed-death ligand 1 (PD-L1), also known as CD274 and B7-H1, can be expressed on the surface of tumour cells and binds to PD-1 receptors found on T-cells. This mechanism is used by tumour cells to evade detection and removal by the immune system. Abcam’s highly specific anti-PD-L1 clone (clone 28-8) has been knockout validated and tested in key applications such as Immunohistochemisty (IHC)1 and Flow Cytometry providing researchers with trusted data and ensuring the accuracy of their results. Developed through a research collaboration with a major pharma company, the PD-L1 antibody will give researchers a high quality tool to further explore the role of PD-L1 in disease progression and treatment. An IHC assay using clone 28-8 has been used to determine PD-L1 expression in clinical trials. Aside from cancer immunology, PD-L1 has also been implicated as having a role in autoimmune diseases and neurological disease.
Abcam is planning further industry partnerships, applying its RabMAb primary antibody technology to make emerging biomarkers available for major disease areas for both research and diagnostic purposes, including other checkpoint inhibitors. RabMAb primary antibodies offer researchers the sensitivity of the rabbit immune system combined with the specificity and consistency of monoclonal antibodies.
Alan Hirzel, CEO of Abcam, said “We want to make specialised, validated reagents, with a translational focus, available for basic research. Collaborating with leading pharmaceutical companies to develop antibodies to critical biomarkers is one important part of this strategy.”
“Our industry partners are working in disease areas with high unmet need, so we are ideally placed to combine their specialist understanding with our novel RabMAb technology to make clones accessible to researchers. In fact, our anti-PD-L1 antibody is highly cited in the market particularly for immunohistochemistry.”
The PD-L1 RabMAb antibody (clone 28-8, Ab205921) antibody can now be purchased from Abcam globally. To find out more, visit www.abcam.com/pdl1
- Phillips, T., et al., 2015. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non–small cell lung cancer. Applied Immunohistochemistry & Molecular Morphology. 23(8), pp 541-9.
T: +44 (0) 1223 696000
Dr. Lynne Trowbridge / Tim Watson
T: +44 (0)20 7457 2861 / +44 (0)20 7866 7861
Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and to improve the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company’s catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support to over 100 countries. The Company was founded in 1998, and now employs over 800 people. Abcam was admitted to AIM in 2005 (AIM: ABC).